Tea Tree
Melaleuca alternifolia
Evidence Rating
C Moderate
Confidence Level
High
Medium-High
Traditions
Western
Last Updated
2/9/2026
Summary
Tea tree oil is the best-studied topical antimicrobial essential oil, with strong evidence for acne (comparable to 5% benzoyl peroxide with fewer side effects) and broad-spectrum antifungal activity. It originates from the Australian Aboriginal tradition, not the European one, but has been assessed by the EMA/HMPC with a traditional use monograph. Commission E and ESCOP have not published dedicated monographs. The primary active compound, terpinen-4-ol, disrupts microbial cell membranes. A critical safety concern is oxidation -- fresh oil is a weak sensitizer, but oxidized oil has 3-fold increased allergenic potency. Contact allergy prevalence in patch-test populations ranges from 0.1% to 3.5%.
⚠️
Drug Interactions
This herb has significant drug interactions. Do not use if you are taking medications without consulting a healthcare provider first. See detailed interaction information below.
Regulatory Status
| Regulatory Body | Status |
|---|---|
| Commission E (Germany) | âś“ Approved |
| ESCOP (European) | âś“ Approved |
| EMA/HMPC (EU) | âś“ Approved |
Metadata
| Field | Value |
|---|---|
| Common Names (English) | Tea Tree Oil, Australian Tea Tree Oil, TTO |
| Common Names (German) | Teebaumol, Australisches Teebaumol |
| Botanical Name | Melaleuca alternifolia (Maiden & Betche) Cheel |
| Plant Family | Myrtaceae |
| Part Used | Essential oil from leaves and terminal branchlets (steam distilled) |
| Evidence Quality Rating | Strong (acne, antifungal) / Moderate (wound healing) — Good RCT data for acne; systematic reviews available; EMA traditional use monograph |
Approved Indications
Commission E (Germany)
- No dedicated monograph published
- Tea tree oil is not part of the traditional German herbal pharmacopoeia (Australian origin)
ESCOP (European Scientific Cooperative on Phytotherapy)
- No dedicated monograph published
EMA/HMPC (European Medicines Agency)
- Traditional Use monograph published
- Indications:
- Treatment of small superficial wounds and insect bites
- Treatment of small boils (furuncles) and mild acne
- Relief of itching and irritation in cases of mild athlete’s foot (tinea pedis)
- Symptomatic treatment of minor inflammation of the oral mucosa
Agreement/Disagreement Between Bodies
- Only EMA/HMPC has issued a monograph — reflecting that this is not a traditional European herb
- Commission E and ESCOP have not assessed it, creating a gap in the traditional European framework
- EMA classification as “traditional use” (not well-established use) reflects the evidence level
Conditions Treated
Primary (Monograph/Evidence-Supported)
- Acne vulgaris (mild to moderate) — strongest clinical evidence
- Tinea pedis (athlete’s foot)
- Onychomycosis (nail fungus) — topical adjunct
- Minor superficial wounds
- Insect bites
Secondary (Clinical/Traditional Use)
- Oral candidiasis
- Bacterial skin infections (impetigo, folliculitis)
- Methicillin-resistant Staphylococcus aureus (MRSA) decolonization [PRELIMINARY]
- Herpes simplex (cold sores) [PRELIMINARY]
- Tinea corporis and tinea cruris
- Dandruff / seborrheic dermatitis
- Demodex folliculitis [PRELIMINARY]
Mechanism of Action
Key Active Compounds
- Terpinen-4-ol (~35-48% of oil) — primary antimicrobial; disrupts cell membranes
- Gamma-terpinene (~14-28%) — antimicrobial
- Alpha-terpinene (~5-13%) — antimicrobial; also a sensitizer precursor upon oxidation
- 1,8-Cineole (eucalyptol) (~0-15%) — antimicrobial; higher levels may increase irritancy
- Alpha-terpineol (~1.5-8%) — antimicrobial
- p-Cymene — oxidation product; indicates degradation
Quality Standards (ISO 4730)
- Terpinen-4-ol content: minimum 30% (higher is better)
- 1,8-Cineole content: maximum 15% (lower is better — reduces irritancy)
Mechanisms
- Membrane disruption: Terpinen-4-ol is the primary agent; it disrupts microbial cell membranes, causing lysis. Non-specific mechanism provides broad-spectrum activity [Source: CMR 19(1):50-62, 2006]
- Anti-inflammatory: Terpinen-4-ol suppresses inflammatory mediators in monocytes
- Antibacterial: Active against Cutibacterium acnes (acne), S. aureus (including MRSA), Streptococcus spp.
- Antifungal: Active against dermatophytes (Trichophyton, Microsporum) and Candida spp.; MIC generally 0.03-0.5%, fungicidal at 0.12-2%
- Antiviral: Activity against herpes simplex virus demonstrated in vitro
Clinical Evidence Summary
Acne Clinical Trials
| Study | Design | N | Comparator | Result |
|---|---|---|---|---|
| Bassett et al. (1990) | RCT, single-blind | 124 | 5% benzoyl peroxide | 5% TTO reduced inflamed lesions by 49% vs. 68% for BP; TTO had slower onset but significantly fewer side effects |
| Enshaieh et al. (2007) | RCT, double-blind | 60 | Placebo | 5% TTO gel significantly better than placebo for total lesion count and acne severity index |
| Comparison studies | Multiple | — | 2% erythromycin | TTO equivalent to topical erythromycin |
Antifungal Clinical Trials
| Study | Design | N | Condition | Result |
|---|---|---|---|---|
| Satchell et al. (2002) | RCT | 158 | Tinea pedis | 25% and 50% TTO significantly better than placebo for clinical response |
| Buck et al. (1994) | RCT | 117 | Onychomycosis | 100% TTO comparable to 1% clotrimazole for clinical improvement |
Systematic Review
- Frontiers in Pharmacology (2023): Systematic review of RCTs confirmed efficacy for acne, tinea pedis, and several other conditions. Safety profile generally favorable with some contact sensitization concerns.
Evidence Assessment
- Acne: Strong evidence from multiple RCTs; comparable to benzoyl peroxide with better tolerability
- Tinea pedis: Moderate-strong evidence from RCTs
- Onychomycosis: Moderate evidence as topical adjunct; complete cure rate is low
- Wound healing (antimicrobial): Based on antimicrobial properties rather than direct wound-healing trials
- MRSA: Promising in vitro; clinical trials limited [NEEDS-RESEARCH]
European vs US/Anglophone Consensus
| Aspect | European Position | US/Anglophone Position |
|---|---|---|
| Regulatory status | EMA traditional use monograph only; not in Commission E or ESCOP | No FDA monograph; widely sold as cosmetic/OTC product |
| Cultural origin | Recognized as Australian, not European tradition | Australian Aboriginal tradition; widely adopted in US/UK |
| Clinical adoption | Growing interest; less traditional recognition than European herbs | Very widely used; one of the most popular essential oils |
| Evidence perception | EMA acknowledges traditional use; formal phytotherapy cautious | Widely accepted; evidence for acne well-known |
| Quality awareness | EU cosmetic regulations (SCCS) address safety; oxidation concerns recognized | Variable quality awareness; many consumers use undiluted |
Notable: Tea tree oil represents a case where the evidence base is strong, but its non-European origin means it lacks the regulatory depth of Commission E/ESCOP assessment that herbs like chamomile or calendula enjoy.
Safety Profile
Contraindications
- Known hypersensitivity to tea tree oil or Myrtaceae
- Not for ingestion (oral toxicity documented)
- Not for use in ear canal
- Avoid use near eyes
Drug Interactions
- No significant systemic drug interactions for topical use
- May theoretically enhance penetration of other topical agents (terpene effect)
Side Effects
- Contact allergic dermatitis: Prevalence 0.1-3.5% in patch-test populations; major sensitizing compounds include ascaridole, terpinolene, alpha-terpinene, and limonene [Source: de Groot 2016, Contact Dermatitis]
- Oxidation increases sensitization: Fresh TTO is a weak-to-moderate sensitizer; oxidation increases allergenic potency up to 3-fold. Exposure to air or light degrades the oil. [Source: CIR Safety Assessment 2021]
- Irritation: Undiluted oil can cause skin irritation; recommended concentration is 5-10% for most applications
- Gynecomastia: Case reports of prepubertal gynecomastia with repeated topical use (mechanism debated; possible endocrine disruption) [CONTESTED]
Pregnancy/Lactation
- Topical use at standard dilutions: Generally considered safe
- Insufficient data for definitive safety assessment
- Avoid undiluted application
Storage Requirements
- Store in dark, airtight containers
- Discard oil that is old or has been exposed to air/light
- Oxidized oil should NOT be used on skin
Clinical Dosage
Topical Preparations
| Form | Concentration | Indication | Notes |
|---|---|---|---|
| Gel (acne) | 5% tea tree oil | Mild-moderate acne | Best-studied concentration |
| Solution (fungal) | 25-50% tea tree oil | Tinea pedis | Higher concentrations needed |
| Solution (nail fungal) | 100% tea tree oil | Onychomycosis | Applied to nail; penetration limited |
| Cream/lotion | 5-10% tea tree oil | General antimicrobial | For minor wounds, insect bites |
| Mouthwash | Dilute solution | Oral mucositis | Use with caution; do not swallow |
Key Commercial Products (Europe)
- Various 5% tea tree oil acne gels available in pharmacies
- Paul Mitchell Tea Tree line (cosmetic)
- Thursday Plantation (Australian brand available in Europe)
Sources
- EMA/HMPC Assessment: Melaleuca alternifolia essential oil
- Carson et al. (2006). Melaleuca alternifolia (Tea Tree) Oil: a Review of Antimicrobial and Other Medicinal Properties. CMR 19(1):50-62. PMC1360273
- Bassett et al. (1990). Comparative study of tea-tree oil vs. benzoylperoxide. Med J Australia. PMID: 2145499
- de Groot (2016). Tea tree oil: contact allergy and chemical composition. Contact Dermatitis. PMID: 27173437
- Frontiers in Pharmacology (2023). Efficacy and safety of tea tree oil: Systematic review of RCTs.
- CIR Safety Assessment (2021). Melaleuca alternifolia-derived ingredients.
- SCCS Scientific Opinion on Tea Tree Oil
Connections
- Antimicrobial mechanism is distinct from the anti-inflammatory focus of Calendula, Witch Hazel, Chamomile
- Oxidation/quality concerns parallel the extract-vs-distillate issue in Witch Hazel
- Compare acne evidence with Chamomile for anti-inflammatory skin evidence